Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB:
496), a human optimization sciences company focused on applying novel and
natural treatment protocols to address a broad range of disorders and
deficiencies with an emphasis on psychedelic medicine, today announced it has
advanced its North American new clinical entity (“NCE”) expansion stratagem via
the formation of a dedicated planning committee (the “Committee”). “We will
look to capitalize on the fragmented nature of the U.S. ketamine clinic
marketplace with the objective of creating a consortium of integrated mood
disorder treatment and research facilities,” Gareth Birdsall, CEO of
Champignon, said in the news release. “By leveraging existing protocols, data
sets and SOPs from our flagship clinic, the Canadian Rapid Treatment Centre of
Excellence, arguably the most advanced integrated mood disorder centre in North
America, we will improve economics, increase patient enrollment and function as
the pre-eminent brick and mortar staging ground for novel molecule discovery
initiatives. Champignon remains bullish on the U.S. marketplace due to
favourable co-payer infrastructure, as well as a vast addressable patient
population.”
To view the full press release, visit http://ibn.fm/mQfIj
About Champignon Brands Inc.
Champignon Brands (CSE: SHRM) is focused on the formulation
and manufacturing of novel ketamine, anaesthetics and adaptogenic delivery
platforms for the nutraceutical and psychedelic medicine while being supported
by a leading psychedelics medicines clinic platform. The Company is pursuing
the development and commercialization of rapid onset treatments capable of
improving health outcomes, such as depression and post-traumatic stress
disorder (“PTSD”), as well as substance and alcohol use disorders. Under a
collaborative research agreement with the University of Miami’s Miller School
of Medicine, the Company is conducting preclinical studies and eventual human
clinical trials, with the objective of demonstrating safety and efficacy of the
combination of psilocybin and cannabidiol in treating mTBI with PTSD or
stand-alone PTSD. Champignon continues to be inspired by sustainability, as its
medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For
more information, visit the Company’s website at www.ChampignonBrands.com.
NOTE TO INVESTORS: The latest news and updates
relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment